Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Figure 5

Subgroup analyses of event-free survival/invasive disease-free survival (EFS/iDFS). (a) EFS/iDFS stratified by lymph node status. LN+: lymph node positive; LN−: lymph node negative; Martin1 2017: subgroup of 1–3 positive LN; Martin2 2017: subgroup of ≥4 positive LN. (b) EFS/iDFS stratified by hormone receptor status. HR+: hormone receptor positive; HR−: hormone receptor negative; IV: inverse-variance method; random: random-effects model; Moreno-Aspitia1 2017: trastuzumab plus lapatinib group; Moreno-Aspitia2 2017: trastuzumab followed by lapatinib group.

(a)

(b)